The immune response to cancer depends on efficient cytotoxic T lymphocytes (CTL), conventional CD4+ T cells and B cells and checkpoint inhibition therapy is aimed at reinvigorating local cytotoxic T cells. This evidence concerns the gene CD4 and cancer.